Prevalent expression of the immunostimulatory MHC class I chain–related molecule is counteracted by shedding in prostate cancer
J. Clin. Invest. Jennifer D. Wu, et al. 114:560 doi:10.1172/JCI22206 [Go to this article.]

Figure 5
Deficiency in NK cell anti-tumor cytotoxicity in prostate cancer patients. Freshly isolated NK cells from peripheral blood of healthy subjects and representative prostate cancer patients (GS 6–7 and GS 8–10) were used as effector cells against M12 target cells in a 4-hour ⁵¹Cr-release assay. Data showed a significant reduction in cancer patient NK cell cytotoxicity against M12 cells. Effector/target: 10/1. *P < 0.05; **P < 0.01.